MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: BIOLOGICAL: Anti-B7H1 Monoclonal Antibody MEDI4736|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|BIOLOGICAL: Tremelimumab
Sponsor: Northwestern University
Collaborators: MedImmune LLC|Avon Breast Cancer Foundation|National Cancer Institute (NCI)